Neurocrine Biosciences Expands Real-World Evidence for VYKAT XR in Prader-Willi Syndrome

  • Neurocrine Biosciences will present research at the FPWR 2026 Annual Research Symposium & Family Conference on October 7-10.
  • PWS-VISTA study will provide baseline demographic and clinical characteristics of PWS patients initiating VYKAT XR.
  • BRAVE-PWS study aims to capture caregiver-reported information on the burden of caring for PWS patients.
  • Integrated analysis will evaluate adverse events of special interest during VYKAT XR treatment.

Neurocrine Biosciences is deepening its commitment to Prader-Willi Syndrome (PWS) with a series of studies aimed at expanding real-world evidence for VYKAT XR, the first and only FDA-approved treatment for hyperphagia in PWS. The company's focus on longitudinal data and caregiver insights reflects a strategic push to solidify VYKAT XR's position in a niche but critical market for rare disease treatments. The research presentations at the FPWR conference highlight Neurocrine's efforts to address unmet needs in PWS management, potentially influencing future regulatory and reimbursement dynamics.

Clinical Evidence
How the PWS-VISTA and BRAVE-PWS studies will impact the long-term adoption of VYKAT XR.
Safety Profile
Whether the integrated analysis of adverse events will reveal new insights into VYKAT XR's safety.
Market Position
The pace at which Neurocrine can establish VYKAT XR as the leading treatment for hyperphagia in PWS.